CSL Limited (FRA:CSJA)
Germany flag Germany · Delayed Price · Currency is EUR
51.00
0.00 (0.00%)
At close: Dec 5, 2025

CSL Limited Company Description

CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma products, gene therapies, and recombinants.

This segment also offers therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas.

The CSL Seqirus segment manufactures, markets, and distributes influenza related products and pandemic services to governments.

The CSL Vifor segment manufactures, markets, and distributes products in the therapeutic areas of iron deficiency and nephrology.

It also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

CSL Limited
Country Australia
Founded 1916
Industry Biological Products, Except Diagnostic Substances
Employees 29,904
CEO Paul McKenzie

Contact Details

Address:
655 Elizabeth Street
Melbourne, 3000
Australia
Phone 61 3 9389 1911
Website csl.com

Stock Details

Ticker Symbol CSJA
Exchange Frankfurt Stock Exchange
Fiscal Year July - June
Reporting Currency USD
SIC Code 2836

Key Executives

Name Position
Paul McKenzie Chief Executive Officer
Ken Lim Chief Financial Officer
Mary Oates Chief Operating Officer
Chris Cooper Head of Investor Relations